Cargando…

Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma

BACKGROUND: The exact regulation network of programmed death 1 (PD-1), programmed death ligand 1 (PD-L1), and programmed death ligand 2 (PD-L2) signaling in immune escape is largely unknown. We aimed to describe the gene expression profiles related to PD-1 as well as its ligands PD-L1 and PD-L2, thu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sheng, Qiu-Ju, Tian, Wen-Yue, Dou, Xiao-Guang, Zhang, Chong, Li, Yan-Wei, Han, Chao, Fan, Yao-Xin, Lai, Ping-Ping, Ding, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Basic Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667459/ https://www.ncbi.nlm.nih.gov/pubmed/33250959 http://dx.doi.org/10.4251/wjgo.v12.i11.1255

Ejemplares similares

Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
por: Yang, Min-Wei, et al.
Publicado: (2019)

Pathological significance of abnormal recepteur d’origine nantais and programmed death ligand 1 expression in colorectal cancer
por: Liu, Yi-Zhi, et al.
Publicado: (2020)

Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinoma
por: Zhang, Wei, et al.
Publicado: (2020)

Mesenchymal stem cells rescue acute hepatic failure by polarizing M2 macrophages
por: Li, Yan-Wei, et al.
Publicado: (2017)

Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression
por: Zheng, Nan-Nan, et al.
Publicado: (2020)

Extracellular vesicles derived from lung cancer cells exposed to intermittent hypoxia upregulate programmed death ligand 1 expression in macrophages
por: Liu, Yuanling, et al.
Publicado: (2021)

P-selectin glycoprotein ligand 1 deficiency prevents development of acute pancreatitis by attenuating leukocyte infiltration
por: Zhang, Xu, et al.
Publicado: (2020)

Infiltration of T Cells and Programmed Cell Death Ligand 1-expressing Macrophages as a Potential Predictor of Lenvatinib Response in Hepatocellular Carcinoma
por: Sung, Pil Soo, et al.
Publicado: (2020)

Programmed death ligand 1 and tumor-infiltrating CD8(+) T lymphocytes are associated with the clinical features in meningioma
por: Zhang, Yaochuan, et al.
Publicado: (2022)

Distinct difference in tumor-infiltrating immune cells between Wilms’ tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies
por: Yokota, Chisato, et al.
Publicado: (2021)

Programmed death ligand 1 gene silencing in murine glioma models reveals cell line-specific modulation of tumor growth in vivo
por: Blomberg, Evelina, et al.
Publicado: (2022)

Clinical significance of soluble programmed cell death‐ligand 1 in hepatitis B virus‐related hepatocellular carcinoma
por: Yang, Zhongxia, et al.
Publicado: (2023)

T‐cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death‐ligand 1 expression in patients with soft tissue sarcomas
por: Pollack, Seth M., et al.
Publicado: (2017)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
por: Liu, Qiang, et al.
Publicado: (2017)

Autophagic cell death induced by reactive oxygen species is involved in hyperthermic sensitization to ionizing radiation in human hepatocellular carcinoma cells
por: Yuan, Guang-Jin, et al.
Publicado: (2017)

Pivotal role of long non-coding ribonucleic acid-X-inactive specific transcript in regulating immune checkpoint programmed death ligand 1 through a shared pathway between miR-194-5p and miR-155-5p in hepatocellular carcinoma
por: Atwa, Sara M, et al.
Publicado: (2020)

Programmed cell death‐ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics
por: Mou, Haibo, et al.
Publicado: (2021)

Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials
por: Zeng, Linyan, et al.
Publicado: (2022)

Y-box binding protein 1 augments sorafenib resistance via the PI3K/Akt signaling pathway in hepatocellular carcinoma
por: Liu, Ting, et al.
Publicado: (2021)

The Programmed Cell Death Ligand-1/Programmed Cell Death-1 Pathway Mediates Pregnancy-Induced Analgesia via Regulating Spinal Inflammatory Cytokines
por: Tan, HuiLing, et al.
Publicado: (2021)

Hemagglutinating virus of Japan‐envelope containing programmed cell death‐ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma
por: Sugii, Narushi, et al.
Publicado: (2020)

The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
por: Hsu, Ping-Chih, et al.
Publicado: (2020)

Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer
por: Bae, Sang Byung, et al.
Publicado: (2016)

The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: He, Shukang, et al.
Publicado: (2021)

Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma
por: Feng, Yong, et al.
Publicado: (2015)

Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
por: Liao, Pei-Fei, et al.
Publicado: (2023)

PD-1 does not mark tumor-infiltrating CD8+ T cell dysfunction in human gastric cancer
por: Shen, Yang, et al.
Publicado: (2020)

ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma
por: Iseda, Norifumi, et al.
Publicado: (2020)

Significance of tumor-infiltrating immunocytes for predicting prognosis of hepatitis B virus-related hepatocellular carcinoma
por: Chen, Qi-Feng, et al.
Publicado: (2019)

Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes
por: Luo, Fan, et al.
Publicado: (2021)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2021)

Bifidobacterium infantis regulates the programmed cell death 1 pathway and immune response in mice with inflammatory bowel disease
por: Zhou, Lin-Yan, et al.
Publicado: (2022)

Programmed death ligand‐1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder
por: Wang, Bo, et al.
Publicado: (2018)

Infiltration of tumor‐associated macrophages is involved in tumor programmed death‐ligand 1 expression in early lung adenocarcinoma
por: Shima, Toshiyuki, et al.
Publicado: (2020)

Physcion increases the sensitivity of hepatocellular carcinoma to sorafenib through miRNA-370/PIM1 axis-regulated glycolysis
por: Pan, Xiao-Ping, et al.
Publicado: (2023)

Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma
por: Zheng, Lin-Lin, et al.
Publicado: (2021)

Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells
por: Sukowati, Caecilia H C, et al.
Publicado: (2021)

Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients
por: Gu, Xiaobin, et al.
Publicado: (2016)

Programmed Death 1 Ligand Expression in the Monocytes of Patients with Hepatocellular Carcinoma Depends on Tumor Progression
por: Asai, Akira, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f52uhfpevgu6n8ri13bm25tt4m